Approximately 3.4 million people in the UK live with T2D1 and most experience complications.2 60% of first complications are due to heart failure (HF) and chronic kidney disease (CKD) resulting from the simultaneous impact of T2D on the cardiovascular and renal organ systems.3
Furthermore, compared with comorbidity-free patients with T2D, cardiorenal disease (HF or CKD) is associated with a greater risk of mortality than even stroke, peripheral arterial disease (PAD) and myocardial infarction (MI).3
In line with this, the complications associated with T2D place a significant burden on not only patients but also the NHS healthcare system, accounting for 80% of the NHS’ spend for the management of T2D.4